A Study of T2000 in Essential Tremor

Essential Tremor Clinical Trial

Official title:

Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00321087
• Other study ID #: T2000-0533
• Status: Terminated
• Phase: Phase 2
• First received: May 1, 2006
• Last updated: January 19, 2014
• Start date: August 2006
• Est. completion date: December 2007

Study information

• Verified date: January 2014
• Source: Taro Pharmaceuticals USA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over a 20 week period.

Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's disease. The medications that are currently used to treat ET work in a small proportion of patients and provide only partial improvement in symptoms. Use of these current medications is also limited by side-effects in many patients.

T2000 is a medication currently under development for the treatment of essential tremor. Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. T2000 was well tolerated for periods up to 20 days and the minimal side-effects seen were those that would be expected for medications in this class.

The current study will evaluate the safety and efficacy of T2000 in patients with moderate to severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 20 weeks. Patient's tremor and neurological examination will be monitored throughout the study. The response to T2000 will be determined by comparing the severity of tremor while patients are receiving T2000 compared to the tremor observed without active medication.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: December 2007
• Est. primary completion date: July 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Confirmed essential tremor by NIH criteria

• Significant functional activity limitation due to ET

• Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment

Exclusion Criteria:

• Patients adequately controlled without side effects on a current ET treatment

• Pregnant patients or patients who may become pregnant during the study

• Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism

• Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers

• Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders

• Patients with seizure disorders

• Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin

• Patient with significant general medical or clinical laboratory abnormalities

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Tremor
• Tremor

Intervention

Drug:
• T2000
Dose escalation from 600 to 1000 mg
• T2000
Placebo followed by T2000 dose escalation from 600 to 1000 mg
• T2000
Placebo followed by dose escalation from 600 to 1000

Locations

Country	Name	City	State
Canada	Investigator Site	London	Ontario
Canada	Investigator Site	Ottawa	Ontario
Canada	Investigator Site	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Taro Pharmaceuticals USA

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. Patients receiving active treatment will be compared to placebo at 2 months of treatment.		Up to 6 months	No
Primary	Response at various dosages will be compared to baseline for all patients.		Up to 6 months	No
Secondary	Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication.		Up to 6 months	Yes